Genvoya

Medical Advocates
Elvitegravir 150 mg (E), Cobicistat 150 mg (C), Emtricitabine 200 mg (F),
and Tenofovir Alafenamide 10 mg (E/C/F/TAF) (Genvoya®)

Genvoya®

Main Page

New and Noteworthy
Journal Data
Elvitegravir/Tenofovir DF/Emtricitabine/Cobicistat
FDA Approval

ARV Main Page

Main New/Newsworthy

Home Page

Last Update: March 02, 2018
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

New and Noteworthy

February 2018

Rare emergence of drug resistance in HIV-1 treatment-naïve patients after 48 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide.
Margot NA, Kitrinos KM, Fordyce M, et al HIV Clin Trials. 2016 Mar;17(2):78-87.

Efficacy and Safety of Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (E/C/F/Taf) in Virologically Suppressed Women.
Hodder S, Squires K, Kityo C, J Acquir Immune Defic Syndr. 2018 Feb 211

Journal Papers, Abstracts, and Commentaries

Rare emergence of drug resistance in HIV-1 treatment-naïve patients after 48 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide.
Margot NA, Kitrinos KM, Fordyce M, et al
HIV Clin Trials. 2016 Mar;17(2):78-87.
Abstract

A Review of the Efficacy and Safety of Genvoya(Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide) in the Management of HIV-1 Infection.
Angione SA, Cherian SM, Özdener AE.
J Pharm Pract. 2017 Jan 1:897190017710519.
Abstract

Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection.
Greig SL, Deeks ED.
Drugs. 2016 Jun;76(9):957-68.
Abstract

Elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide for the treatment of HIV in adults.
Bonora S, Calcagno A, Trentalange A, Perri GD.
Expert Opin Pharmacother. 2015 Dec 5
Abstract

A Randomized , Open-label Trial to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide plus Darunavir in Treatment-Experienced HIV-1 Infected Adults.
Huhn GD, Tebas P, Gallant J, et al
J Acquir Immune Defic Syndr. 2016 Oct 6.
Abstract

Switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected patients with renal impairment:
48 week results from a single-arm, multi-center, open-label, Phase 3 study.
Pozniak A, Arribas JR, Gathe J, et al
J Acquir Immune Defic Syndr. 2015 Nov 30
Abstract

FDA Approval

NEWS RELEASE
U.S. Food and Drug Administration Approves Gilead’s Single Tablet Regimen Genvoya® (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide) for Treatment of HIV-1 Infection (November 05, 2015)

ARV Main Page

Main New/Newsworthy

Home Page

Elvitegravir 150 mg (E), Cobicistat 150 mg (C), Emtricitabine 200 mg (F),
and Tenofovir Alafenamide 10 mg (E/C/F/TAF) (Genvoya®)

NEWS RELEASE U.S. Food and Drug Administration Approves Gilead’s Single Tablet Regimen Genvoya® (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide) for Treatment of HIV-1 Infection (November 05, 2015)

NEWS RELEASE
U.S. Food and Drug Administration Approves Gilead’s Single Tablet Regimen Genvoya® (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide) for Treatment of HIV-1 Infection (November 05, 2015)